Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +8.84%12 Equity-to-Asset is 0.80 as of Jun. 2026. GuruFocus rates ALMR with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 852 Medical Devices & Instruments companies, Alamar Biosciences ranks better than 75.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alamar Biosciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $312.86 Mil. Alamar Biosciences's Total Assets for the quarter that ended in Jun. 2026 was $390.98 Mil.
Therefore, Alamar Biosciences's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.80.
The historical rank and industry rank for Alamar Biosciences's Equity-to-Asset or its related term are showing as below:
ALMR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.14 Med: -0.92 Max: 0.8
Current: 0.8
During the past 2 years, the highest Equity to Asset Ratio of Alamar Biosciences was 0.80. The lowest was -1.14. And the median was -0.92.
ALMR's Equity-to-Asset is ranked better than 75.94% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ALMR: 0.80
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Alamar Biosciences Equity-to-Asset Related Terms
Alamar Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Equity-to-Asset Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Equity-to-Asset
-0.89
-1.14
Alamar Biosciences Quarterly Data
Mar25
Jun25
Mar26
Jun26
Equity-to-Asset
-
-
-0.96
0.80
ALMR vs ESTA, NVCR, BFLY: Equity-to-Asset Comparison
For the Medical Devices subindustry, Alamar Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Alamar Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a Equity-to-Asset of 0.80 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alamar Biosciences and its competitors. According to the industry distribution chart, Alamar Biosciences ranks #205 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Alamar Biosciences' Equity-to-Asset too high?
Alamar Biosciences' current Equity-to-Asset is 0.80. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Alamar Biosciences' value of 0.80 is 25% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #205 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Equity-to-Asset compare to ESTA and NVCR?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #205 out of 852 companies for Equity-to-Asset. This places Alamar Biosciences in the top 24% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Alamar Biosciences' value of 0.80 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Equity-to-Asset of 0.80 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Equity-to-Asset is 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Equity-to-Asset of 0.80. The current Equity-to-Asset is 0.80 and 25% above the Medical Devices & Instruments industry median of 0.64. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Equity-to-Asset is 0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score
Get the complete analysis for ALMR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
